NICE Approves Dual Immunotherapy for Aggressive Bowel Cancer
, 2025-04-23 09:27:00 The National Institute for Health and Care Excellence (NICE) has recommended nivolumab (Opdivo) plus ipilimumab (Yervoy) for some people in England with advanced colorectal cancer. The treatment is recommended for adults with untreated, unresectable, or metastatic colorectal cancer that shows high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). In final draft…